ONCOC4, INC.
- Country
- π¦πΊAustralia
- Ownership
- Private
- Established
- 2020-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://oncoc4.com
Clinical Trials
8
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 204
- Registration Number
- NCT06635785
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈHighlands Oncology Group, Springdale, Arkansas, United States
πΊπΈUniversity of Florida UF Health Cancer Center, Gainesville, Florida, United States
Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06352359
- Locations
- πΊπΈ
University of California at Davis Cancer Center, Sacramento, California, United States
πΊπΈUF Health Cancer Center, University of Florida, Gainesville, Florida, United States
πΊπΈAdventHealth Medical Group Oncology Research at Celebration, Kissimmee, Florida, United States
Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- OncoC4, Inc.
- Registration Number
- NCT06219499
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
- Conditions
- MelanomaNon Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal CarcinomaFallopian Tube CancerEndometrial CancerCervical CancerRenal Cell CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05858736
- Locations
- π¦πΊ
St. Vincent's Private Hospital, Darlinghurst, New South Wales, Australia
π¦πΊMater Misericordiae Ltd., Brisbane, Queensland, Australia
π¦πΊTasman Oncology Research, Southport, Queensland, Australia
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 141
- Registration Number
- NCT05682443
- Locations
- πΊπΈ
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
πΊπΈRocky Mountain Cancer Centers USOR, Aurora, Colorado, United States
πΊπΈMoffitt Cancer Cancer, Tampa, Florida, United States
- Prev
- 1
- 2
- Next